Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growth
- New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA date
- Q2 2024 Cash Flow from Operations of $1.3 million, including the payment of one-time $2.0 million NDA filing fee for ET-400
- Management to hold conference call today at 4:30pm ET
- 產品銷售和版稅收入爲910萬美元，比2023年第二季度增長了40%，並連續第14個季度實現了產品銷售增長。
- Et-400的新藥申請被美國食品和藥物管理局（FDA）接受，並分配了2025年2月28日的PDUFA日。
- 2024年第二季度運營現金流爲130萬美元，其中包括支付獨一無二的200萬美元的Et-400新藥申請費。
- 管理層將於今天下午4:30 ET召開電話會議。
DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2024.
伊頓製藥公司（"伊頓"或"公司"）（納斯達克：ETON）是一家專注於開發和商業化罕見疾病治療方法的創新制藥公司，今日宣佈了截至2024年6月30日的財務業績。
"We are pleased to report another quarter of record product sales as Carglumic Acid and ALKINDI SPRINKLE continue to deliver impressive growth. During the quarter we also launched PKU GOLIKE under our commercial infrastructure and received a favorable reception from the PKU community. Our five existing commercial products have the potential to deliver strong organic growth for many years to come, and we plan to accelerate that growth with our internal pipeline and business development activities," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
"我們很高興報告再次實現產品銷售額的新紀錄，Carglumic Acid和ALKINDI SPRINKLE繼續取得驚人的增長。在本季度期間，我們還在商業基礎設施下啓動了PKU GOLIKE，並獲得了PKU社區的積極反響。我們的五個現有商業產品有潛力提供強勁的有機增長，並計劃通過內部管道和業務發展活動加速增長，"伊頓製藥公司首席執行官肖恩·布林傑爾森（Sean Brynjelsen）說。
"We have made tremendous recent progress advancing our pipeline, which we believe will set us up to deliver even greater growth in 2025 and beyond. Our NDA for ET-400 was recently accepted for review and assigned a target action date in early 2025. Pre-launch commercialization activities for the product are underway and we anticipate launching it shortly after the expected approval. In addition, our ET-600 product candidate is now ready to start its pivotal study in Q3, after passing a pilot study earlier this year. This should allow for an early 2025 NDA submission, which would further boost the Company's long-term growth prospects" concluded Brynjelsen.
"我們在推進管道方面取得了驚人的進展，我們相信這將使我們能夠在2025年及以後實現更大的增長。我們的Et-400新藥申請最近被接受進行審查，並分配了2025年初的目標行動日期。產品的預發行商業活動正在進行中，我們預計會在批准後不久推出該產品。此外，我們的Et-600產品候選人現已準備好在Q3開始其關鍵研究，此前已通過今年早些時候的試點研究。這應該可以讓公司在2025年初提交新藥申請，從而進一步提高公司的長期增長前景，"布林傑爾森總結道。
Second quarter and Recent Business Highlights
第二季度及近期業務亮點
14th straight quarter of sequential growth in product sales and royalty revenue. Eton reported second quarter 2024 product sales of $9.1 million, representing 40% growth over the prior year period, and 14% over the first quarter of 2024, driven primarily by the ongoing growth of ALKINDI SPRINKLE and Carglumic Acid. The Company expects to continue to see sequential quarter-over-quarter growth of product sales through the remainder of 2024 and beyond.
產品銷售和版稅收入連續第14個季度實現了順序增長。伊頓報告了2024年第二季度銷售額910萬美元，比去年同期增長了40％，比2024年第一季度增長了14％，主要受到ALKINDI SPRINKLE和Carglumic Acid不斷增長的推動。公司預計將在2024年剩餘時間和未來繼續看到產品銷售連續季度增長。
NDA for ET-400 submitted and accepted by the FDA. During the second quarter of 2024, Eton submitted an NDA for ET-400, its proprietary patented formulation of hydrocortisone oral solution. The FDA accepted the NDA and assigned it a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025. Eton anticipates initiating production of launch quantities in the fourth quarter of 2024, to allow for a commercial launch promptly after the expected approval. Eton believes the introduction of ET-400 will allow the Company to capture a greater percentage of the oral hydrocortisone market and, together with ALKINDI SPRINKLE, can achieve combined peak sales of more than $50 million annually.
Et-400的新藥申請已在2024年第二季度提交併獲得了FDA的接受。FDA已經分配了處方藥用戶費法案（PDUFA）的目標行動日期爲2025年2月28日。伊頓預計在2024年第四季度開始生產推出數量，以便在預期獲得批准後迅速商業化推出。伊頓認爲，推出Et-400將使公司能夠佔據更大比例的口服氫化可的松市場，並與ALKINDI SPRINKLE一起實現每年超過5000萬美元的停售高峰。
Acceleration of growth for ALKINDI SPRINKLE. ALKINDI SPRINKLE reported 63% year over year revenue growth in Q2 2024. Product sales are benefiting from the Company's internal sales force, which has now been in place for more than a year and has seen increased production, as well as recent initiatives including the launch of the sampling program and the Company's strong presence at Endocrinology medical conferences and patient advocacy events in the first half of 2024.
ALKINDI SPRINKLE的增長加速。ALKINDI SPRINKLE在2024年第二季度報告了63％的年同比營收增長。產品銷售受益於公司內部銷售人員已經存在一年多並已經看到增加生產以及最近的倡議，包括啓動抽樣計劃以及在2024年上半年內分別在內分泌學醫學會和患者倡導活動中強大的出席。
Continued Carglumic Acid outperformance. Sales of Carglumic Acid continue to exceed the Company's expectations. The product reported strong growth in the second quarter and has already added additional patients in the third quarter of 2024. The recent launches of Betaine Anhydrous, Nitisinone, and now PKU GOLIKE have also helped increase the frequency of the Company's interactions with potential Carglumic Acid prescribers.
Carglumic Acid持續表現優異。Carglumic Acid的銷售量仍然超過了公司的預期。產品在第二季度報告了強勁增長，並已在2024年第三季度增加了額外的患者。貝他因無水、尼西諾和現在的PKU GOLIKE推出還幫助增加了公司與潛在Carglumic Acid處方者的互動頻率。
Launched PKU GOLIKE, a medical formula for patients with phenylketonuria (PKU). After acquiring PKU GOLIKE in the first quarter, the Company launched the product under Eton's commercial infrastructure in April at the Genetic Metabolic Dieticians International Conference. The product has been well received and the Company has already seen an increased number of patient referrals since the initiation of its promotional activities.
推出PKU GOLIKE，一種針對苯丙酮尿症（PKU）患者的醫療配方。在第一季度收購PKU GOLIKE後，公司在4月份在遺傳代謝營養師國際會議上在商業基礎架構下推出了該產品。該產品受到好評，自促銷活動啓動以來，公司已經看到了更多的患者轉介。
Anticipated initiation of ET-600 pivotal study. Eton expects to initiate a pivotal bioequivalence study for ET-600, the Company's product candidate for diabetes insipidus, in the third quarter. Earlier this year, the product passed its pilot bioequivalence study, and the company anticipates submitting an NDA for the product in early 2025
預計啓動Et-600關鍵研究。伊頓預計在第三季度啓動Et-600的關鍵生物等效性研究，該公司將該產品作爲治療尿崩症的候選人。今年早些時候，該產品通過了試點生物等效性研究，公司預計將在2025年初提交新藥申請。
Second Quarter Financial Results
第二季度財務業績
Net Revenue: Net sales for the second quarter of 2024 were $9.1 million compared to $12.0 million in the prior year period. Net sales in the prior year period included $5.5 million of licensing payments related to the divestment of Eton's neurology product royalties.
淨收入：2024年第二季度淨銷售額爲910萬美元，而上年同期爲1200萬美元。上年同期的淨銷售額包括與伊頓神經病學產品版稅剝離相關的550萬美元授權金。
Product sales and royalty revenue were $9.1 million for the second quarter of 2024, an increase of 40% compared to $6.5 million in the prior year period, and an increase of 14% over the first quarter of 2024. The year-over-year increase in product sales and royalty revenue was primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid.
產品銷售和版稅收入爲2024年第二季度910萬美元，比去年同期增長了40％，比2024年第一季度增長了14％。同比增長主要得益於ALKINDI SPRINKLE和Carglumic Acid的增長。
Gross Profit: Gross profit for the second quarter of 2024 was $5.6 million compared to $9.7 million in the prior year period.
毛利潤：2024年第二季度毛利潤爲560萬美元，而上年同期爲970萬美元。
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2024 were $3.0 million compared to $1.1 million in the prior year period. The increase was primarily due to the payment of a $2.0 million NDA filing fee for ET-400.
研發（R＆D）支出：2024年第二季度的R＆D支出爲300萬美元，而上年同期爲110萬美元。增加主要是由於支付了Et-400新藥申請費20萬美元。
General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2024 were $5.6 million compared to $4.7 million in the prior year period, mainly due to increased sales and marketing expenses, employee-related expenses, and one-time legal fees related to business development activities.
總務和行政費用（G＆A）：2024年第二季度的G＆A費用爲560萬美元，而去年同期爲470萬美元，主要是由於銷售和營銷費用、員工相關費用以及與業務發展活動有關的一次性法律費用增加。
Net Income: Net loss for the second quarter of 2024 was $2.9 million or $0.11 per basic and diluted share, including the $2.0 million ET-400 filing fee. In the prior year period, net income was $4.6 million, or $0.18 per basic and diluted share, and included $5.5 million from the sale of Eton's royalty interests.
淨收益：2024年第二季度，扣除200萬美元的Et-400新藥申請費用，淨虧損爲290萬美元或每股基本和攤薄股份11美分。去年同期，淨收入爲460萬美元，每股基本和攤薄股份爲18美分，包括從伊頓版稅利益出售中獲得的550萬美元。
Cash Position: As of June 30, 2024, Eton had cash and cash equivalents of $17.7 million. The Company generated $1.3 million of operating cash flow during the quarter, including the $2.0 million ET-400 filing fee. The company expects to continue to generate positive operating cash flow for the remainder of 2024.
現金持倉：截至2024年6月30日，伊頓的現金及現金等價物爲1770萬美元。公司本季度產生了130萬美元的營運現金流，其中包括200萬美元的Et-400申報費。公司預計在2024年的餘下時間繼續產生正面的營運現金流。
| Conference Call and Webcast Information | |
| As previously announced, Eton Pharmaceuticals will host a its second quarter 2024 conference call as follows: | |
| Date | August 8, 2024 |
| Time | 4:30 p.m. ET (3:30 p.m. CT) |
| Dial in* (Audio Only) | Click Here |
| Webcast: | Click Here |
| 電話會議和網絡直播信息 | |
| 正如之前宣佈的那樣，伊頓製藥將按如下方式舉行2024年第二季度電話會議： | |
| 日期 | 2024年8月8日 |
| 時間 | 美國東部時間下午4:30（中部時間下午3:30） |
| 僅限電話撥入*（僅音頻） | 點擊這裏 |
| 網絡直播： | 點擊這裏 |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
除了在電話會議上回答參會人員的實時提問外，管理層還將回答投資者在電子郵件中發送的問題。投資者可以將問題發送到：investorrelations@etonpharma.com。
The live webcast can also be accessed on the Investors section of Eton's website at . An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter.
現場網絡直播也可以在伊頓製藥公司的投資者板塊上獲得。活動完成後約兩個小時，伊頓製藥公司網站上將有存檔網絡直播，存檔時間爲30天。
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
*電話會議參與者應進行註冊，以獲取電話撥入和密碼詳細信息。請務必使用有效的電子郵件地址進行註冊。
About Eton Pharmaceuticals
關於伊頓製藥公司
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, please visit our website at .
伊頓是一家專注於研發和商業化罕見病治療的創新性製藥公司。該公司目前擁有五種罕見病產品：ALKINDI SPRINKLE，PKU GOLIKE，Carglumic Acid，Betaine Anhydrous和Nitisinone。公司目前處於三個尾期開發的產品，包括ET-400，ET-600和ZENEO水楊酸巴利昂自動注射器。欲了解更多信息，請訪問我公司網站。
Forward-Looking Statements
前瞻性聲明
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates, the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新聞稿中的有關非歷史事實的事項的聲明屬於「前瞻性聲明」，涉及伊頓能夠承擔某些活動並實現某些目標和目的的預期能力。這些聲明包括但不限於涉及伊頓業務策略，伊頓計劃發展和商業化其產品候選者，伊頓產品候選者的安全性和有效性，伊頓在監管申報和批准方面的計劃和預期時間以及伊頓產品候選者市場規模和增長潛力的聲明。由於此類聲明存在風險和不確定性，實際結果可能與此類前瞻性聲明所表達或暗示的結果有所不同。本新聞稿旨在識別前瞻性聲明的單詞，例如「相信」，「預計」，「計劃」，「期望」，「打算」，「將」，「目標」，「潛力」等。這些前瞻性聲明基於伊頓目前的預期並涉及可能從未實現或可能證明不正確的假設。由於各種風險和不確定性，實際結果和事件的時間可能因正在進行發現，開發和商業化安全，有效用於人類治療的藥物的過程以及圍繞此類藥物建立業務所涉及的風險而與此類前瞻性聲明所預計的結果有所不同。有關伊頓發展項目和財務狀況的這些和其他風險在伊頓向證券交易委員會提交的文件中有更詳細的描述。本新聞稿中包含的所有前瞻性聲明僅適用於它們發表的日期。伊頓不承擔更新這些聲明以反映發生或存在於發表之後的事件或情況的義務。
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
投資者關係:
英未泰客，內部溝通公司
T: 212-452-2793
E: lwilson@insitecony.com
|
Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) (Unaudited) | |||||||||||||||
| For the three months ended | For the six months ended | ||||||||||||||
| June 30, | June 30, | June 30, | June 30, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues: | |||||||||||||||
| Licensing revenue | $ | — | $ | 5,500 | $ | — | $ | 5,500 | |||||||
| Product sales and royalties | 9,074 | 6,497 | 17,040 | 11,801 | |||||||||||
| Total net revenues | 9,074 | 11,997 | 17,040 | 17,301 | |||||||||||
| Cost of sales: | |||||||||||||||
| Licensing revenue | — | — | $ | — | — | ||||||||||
| Product sales and royalties | 3,448 | 2,315 | 6,407 | 4,273 | |||||||||||
| Total cost of sales | 3,448 | 2,315 | 6,407 | 4,273 | |||||||||||
| Gross profit | 5,626 | 9,682 | 10,633 | 13,028 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 2,970 | 1,125 | 3,621 | 1,660 | |||||||||||
| General and administrative | 5,591 | 4,674 | 10,747 | 10,019 | |||||||||||
| Total operating expenses | 8,561 | 5,799 | 14,368 | 11,679 | |||||||||||
| Income (loss) from operations | (2,935) | 3,883 | (3,735) | 1,349 | |||||||||||
| Other income (expense): | |||||||||||||||
| Other income | — | 800 | — | 800 | |||||||||||
| Interest expense, net | (52) | (124) | (63) | (250) | |||||||||||
| Total other income (expense) | (52) | 676 | (63) | 550 | |||||||||||
| Income (loss) before income tax expense | (2,987) | 4,559 | (3,798) | 1,899 | |||||||||||
| Income tax expense | 54 | — | 54 | — | |||||||||||
| Net income (loss) | $ | (3,041) | $ | 4,559 | $ | (3,852) | $ | 1,899 | |||||||
| Net income (loss) per share, basic | $ | (0.12) | $ | 0.18 | $ | (0.15) | $ | 0.07 | |||||||
| Weighted average number of common shares outstanding, basic | 25,778 | 25,593 | 25,771 | 25,560 | |||||||||||
| Net income (loss) per share, diluted | $ | (0.12) | $ | 0.18 | $ | (0.15) | $ | 0.07 | |||||||
| Weighted average number of common shares outstanding, diluted | 25,778 | 25,983 | 25,771 | 25,949 | |||||||||||
| 伊敦製藥公司。 經簡化的損益表 2024年4月27日 (未經審計) | |||||||||||||||
| 截至2023年1月31日三個月的 | 截至2022年4月30日六個月 | ||||||||||||||
| 6月30日, | 6月30日, | 6月30日, | 6月30日, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| 營收： | |||||||||||||||
| 許可收入 | $ | — | $ | 5,500 | $ | — | $ | 5,500 | |||||||
| 產品銷售和特許權使用費 | 9,074 | 6,497 | 17,040 | 11,801 | |||||||||||
| 總淨收入 | 9,074 | 11,997 | 17,040 | 17,301 | |||||||||||
| 銷售成本： | |||||||||||||||
| 許可收入 | — | — | $ | — | — | ||||||||||
| 產品銷售和特許權使用費 | 3,448 | 2,315 | 6,407 | 4273 | |||||||||||
| 銷售成本合計 | 3,448 | 2,315 | 6,407 | 4273 | |||||||||||
| 毛利潤 | 5,626 | 9,682 | 10,633 | 13,028 | |||||||||||
| 營業費用： | |||||||||||||||
| 研發 | 2,970 | 1,125 | 3,621 | 1,660 | |||||||||||
| 普通和管理 | 5,591 | 4,674 | 10,747 | 10,019 | |||||||||||
| 營業費用總計 | 8,561 | 5,799 | 14,368 | 11,679 | |||||||||||
| 營業收支（虧損） | （2,935） | 3,883 | （3,735） | 1,349 | |||||||||||
| 其他收入（支出）： | |||||||||||||||
| 其他收入 | — | 800 | — | 800 | |||||||||||
| 利息費用，淨額 | （52） | (124) | （63） | （250） | |||||||||||
| 其他收入（支出）總額 | （52） | 676 | （63） | 550 | |||||||||||
| 收入（虧損）在所得稅開支之前 | （2,987） | 4,559 | (3,798) | 1,899 | |||||||||||
| 所得稅費用 | 54 | — | 54 | — | |||||||||||
| 淨利潤（損失） | $ | (3,041) | $ | 4,559 | $ | (3,852) | $ | 1,899 | |||||||
| 基本每股淨收益（虧損） | $ | (0.12) | $ | 0.18 | $ | （0.15） | $ | 0.07 | |||||||
| 加權平均基本普通股股本 | 25,778 | 25,593 | 25,771 | 25,560 | |||||||||||
| 每股淨利潤，攤薄 | $ | (0.12) | $ | 0.18 | $ | （0.15） | $ | 0.07 | |||||||
| 加權平均攤薄普通股股本 | 25,778 | 25,983 | 25,771 | 25,949 | |||||||||||
|
Eton Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) | |||||||
| June 30, 2024 | December 31, 2023 | ||||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 17,694 | $ | 21,388 | |||
| Accounts receivable, net | 4,873 | 3,411 | |||||
| Inventories | 2,068 | 911 | |||||
| Prepaid expenses and other current assets | 799 | 1,129 | |||||
| Total current assets | 25,434 | 26,839 | |||||
| Property and equipment, net | 45 | 58 | |||||
| Intangible assets, net | 6,122 | 4,739 | |||||
| Operating lease right-of-use assets, net | 210 | 92 | |||||
| Other long-term assets, net | 12 | 12 | |||||
| Total assets | $ | 31,823 | $ | 31,740 | |||
| Liabilities and stockholders'equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,133 | $ | 1,848 | |||
| Debt, net of unamortized discount | 4,658 | 5,380 | |||||
| Accrued liabilities | 11,425 | 9,013 | |||||
| Total current liabilities | 18,216 | 16,241 | |||||
| Operating lease liabilities, net of current portion | 145 | 22 | |||||
| Total liabilities | 18,361 | 16,263 | |||||
| Commitments and contingencies (Note 11) | |||||||
| Stockholders'equity | |||||||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 25,745,802 and 25,688,062 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 26 | 26 | |||||
| Additional paid-in capital | 121,358 | 119,521 | |||||
| Accumulated deficit | (107,922) | (104,070) | |||||
| Total stockholders'equity | 13,462 | 15,477 | |||||
| Total liabilities and stockholders'equity | $ | 31,823 | $ | 31,740 | |||
| 伊敦製藥公司。 精簡資產負債表 (以千爲單位，除每股數據外) | |||||||
| 2024年6月30日 | 2023年12月31日 | ||||||
| (未經審計) | |||||||
| 資產 | |||||||
| 流動資產： | |||||||
| 現金及現金等價物 | $ | 17,694 | $ | 21,388 | |||
| 應收賬款淨額 | 4,873 | 3,411 | |||||
| 存貨 | 2,068 | 911 | |||||
| 資產預付款和其他流動資產的變動 | 799 | 1,129 | |||||
| 總流動資產 | 25,434 | 26,839 | |||||
| 資產和設備，淨值 | 45 | 58 | |||||
| 無形資產, 淨額 | 6,122 | 4,739 | |||||
| 經營租賃使用權資產，淨值 | 210 | 92 | |||||
| 其他開多期資產，淨值 | 12 | 12 | |||||
| 總資產 | $ | 31,823 | $ | 31740 | |||
| 負債和股東權益 | |||||||
| 流動負債: | |||||||
| 應付賬款 | $ | 2,133 | $ | 1,848 | |||
| 減計折價後的債務淨額 | 4,658 | 5,380 | |||||
| 應計負債 | 11,425 | 9,013 | |||||
| 流動負債合計 | 18,216 | 16241 | |||||
| 經營租賃負債，淨值超過流動資產 | 145 | 22 | |||||
| 負債合計 | 18,361 | 16263 | |||||
| 承諾和業務準備金（注11） | |||||||
| 股東權益 | |||||||
| 普通股，每股面值0.001美元；授權股份爲5000萬股；截至2024年6月30日和2023年12月31日，已發行和流通股份分別爲25,745,802股和25,688,062股。 | 26 | 26 | |||||
| 額外實收資本 | 121,358 | 119521 | |||||
| 累積赤字 | （107,922） | （104070） | |||||
| 股東權益總計 | 13,462 | 15477 | |||||
| 負債和股東權益合計 | $ | 31,823 | $ | 31740 | |||
|
Eton Pharmaceuticals, Inc. Condensed Statements of Cash Flows (In thousands) (Unaudited) | |||||||
| Six months ended | Six months ended | ||||||
| June 30, 2024 | June 30, 2023 | ||||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (3,852) | $ | 1,899 | |||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||
| Stock-based compensation | 1,661 | 1,657 | |||||
| Depreciation and amortization | 513 | 385 | |||||
| Non-cash lease expense | 36 | 39 | |||||
| Debt discount amortization | 48 | 61 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (1,462) | (1,232) | |||||
| Inventories | (1,157) | (259) | |||||
| Prepaid expenses and other assets | 330 | 423 | |||||
| Accounts payable | 284 | 537 | |||||
| Accrued liabilities | 2,381 | 2,045 | |||||
| Net cash (used in) provided by operating activities | (1,218) | 5,555 | |||||
| Cash flows from investing activities | |||||||
| Purchases of product license rights | (1,868) | — | |||||
| Purchases of property and equipment | (14) | — | |||||
| Net cash used in investing activities | (1,882) | — | |||||
| Cash flows from financing activities | |||||||
| Repayment of long-term debt | (770) | (385) | |||||
| Proceeds from employee stock purchase plan and stock option exercises | 176 | 272 | |||||
| Payment of tax withholding related to net share settlement of stock option exercises | — | (181) | |||||
| Net cash used in financing activities | (594) | (294) | |||||
| Change in cash and cash equivalents | (3,694) | 5,261 | |||||
| Cash and cash equivalents at beginning of period | 21,388 | 16,305 | |||||
| Cash and cash equivalents at end of period | $ | 17,694 | $ | 21,566 | |||
| Supplemental disclosures of cash flow information | |||||||
| Cash paid for interest | $ | 362 | $ | 426 | |||
| Cash paid for income taxes | $ | — | $ | — | |||
| Supplemental disclosures of non-cash transactions in investing and financing activities | |||||||
| Right-of-use assets and liabilities obtained due to lease renewal | $ | 153 | $ | — | |||
| 伊敦製藥公司。 現金流量簡明報表 （以千爲單位） (未經審計) | |||||||
| 截至2022年6月30日的六個月 | 截至2022年6月30日的六個月 | ||||||
| 2024年6月30日 | 2023年6月30日 | ||||||
| 經營活動現金流 | |||||||
| 淨虧損 | $ | (3,852) | $ | 1,899 | |||
| 調整使淨虧損轉爲經營活動產生的現金流量: | |||||||
| 以股票爲基礎的報酬計劃 | 1,661 | 1,657 | |||||
| 折舊和攤銷 | 513 | 385 | |||||
| 非現金租賃費用 | 36 | 39 | |||||
| 債務折扣攤銷 | 48 | 61 | |||||
| 經營性資產和負債變動: | |||||||
| 應收賬款 | (1,462) | (1,232) | |||||
| 存貨 | (-1,157) | (259) | |||||
| 預付款項和其他資產 | 330 | 423 | |||||
| 應付賬款 | 284 | 537 | |||||
| 應計負債 | 2,381。 | 2,045 | |||||
| 經營活動產生的現金流量淨額 | （1,218） | 5,555 | |||||
| 投資活動現金流量 | |||||||
| 購買產品許可權 | (1,868) | — | |||||
| 購買固定資產 | (14) | — | |||||
| 投資活動產生的淨現金流出 | (1,882) | — | |||||
| 籌資活動現金流量 | |||||||
| 償還長期債務 | （770） | (385) | |||||
| 來自員工股票購買計劃和股票期權行權的收益 | 176 | 272 | |||||
| 支付納稅代扣與股票期權行權淨結算有關的稅款 | — | (181) | |||||
| 籌集資金淨額 | (594) | （294） | |||||
| 現金及現金等價物淨變動額 | (3,694) | 5,261 | |||||
| 期初現金及現金等價物餘額 | 21,388 | 16,305 | |||||
| 期末現金及現金等價物 | $ | 17,694 | $ | 來自相關方的應付款項 | |||
| 現金流補充資料披露 | |||||||
| 支付的利息現金 | $ | 362 | $ | 426 | |||
| 支付的所得稅費用 | $ | — | $ | — | |||
| 投資和籌資活動的非現金交易的補充披露 | |||||||
| 由於租賃續期而獲得的租用權資產和負債 | $ | 153 | $ | — | |||
Source: Eton Pharmaceuticals
來源：伊頓製藥公司
譯文內容由第三人軟體翻譯。
